Prescription drugs have become increasingly expensive every year, and yet there are few regulatory controls at the state level to manage prices. To address the high costs of drug prices, policymakers in other states have been exploring a newer strategy that’s growing in popularity: affordability review boards.
The fourth and final brief in our Drug Pricing Policy Solution series discusses how these boards can cap costs on prescriptions and increase transparency.